第一作者机构：[1]Peking Univ Canc Hosp & Inst, Dept Renal Cell Carcinoma & Melanoma, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Cui C-L.,Li Z.,Wu N.,et al.Neoadjuvant toripalimab plus axitinib in patients (pts) with resectable mucosal melanoma (MuM): Updated findings of a single-arm, phase II trial[J].ANNALS OF ONCOLOGY.2022,33(7):S908-S908.doi:10.1016/j.annonc.2022.07.922.
APA：
Cui, C-L.,Li, Z.,Wu, N.,Li, M.,Chen, X....&Guo, J..(2022).Neoadjuvant toripalimab plus axitinib in patients (pts) with resectable mucosal melanoma (MuM): Updated findings of a single-arm, phase II trial.ANNALS OF ONCOLOGY,33,(7)
MLA：
Cui, C-L.,et al."Neoadjuvant toripalimab plus axitinib in patients (pts) with resectable mucosal melanoma (MuM): Updated findings of a single-arm, phase II trial".ANNALS OF ONCOLOGY 33..7(2022):S908-S908
医学